Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies
Frontiers in Pharmacology · 14.08.2025 · 16
DOI: 10.3389/fphar.2025.1612089 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.08.2025. Verfasst von Haifeng Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drug-tolerant persister (DTP) cells are a subpopulation of cancer cells capable of surviving therapeutic stress through reversible, non-genetic adaptations. These cells contribute to minimal residual disease and eventual tumor relapse. Understanding the mechanisms that govern the entry into and exit from the DTP state—such as epigenetic remodeling, metabolic rewiring, and transcriptional plasticity—reveals actionable vulnerabilities. This article reviews the biological basis of DTP reversibility, outlines the major challenges in targeting these cells, and proposes innovative therapeutic strategies including epigenetic inhibitors, metabolic disruptors, and adaptive dosing regimens. We also highlight the importance of biomarker development and dynamic monitoring. Targeting DTP cells at their reversible stage may prevent permanent resistance, offering a promising avenue to improve treatment durability and patient outcomes in cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
- Qingdao Hospital, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
- Department of Anesthesia, Affiliated Hospital of Qingdao University, Qingdao, China.
Zitieren
APA
Li, H., Xu, W., Cheng, W., Yu, G., & Tang, D. (2025). Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1612089
Vancouver
Li H, Xu W, Cheng W, Yu G, Tang D. Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1612089
BibTeX
@article{Li2025,
author = {Li, Haifeng and Xu, Wenlong and Cheng, Wenqi and Yu, Guanxiao and Tang, Dongmei},
title = {Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1612089}
}
EUVIMED